人表皮生长因子受体2(HER2)低表达乳腺癌的[68Ga]Ga-ABY-025 HER2 PET显像:一项先导研究结果
这项前瞻性先导研究纳入10例HER2低表达转移性乳腺癌患者,评估[68Ga]Ga-ABY-025 PET/CT的可行性与安全性。注射200 MBq后3小时显像,未发生不良事件,所有患者均见示踪剂摄取病灶且存在异质性;8例经活检确认HER2低表达。
要点
- 10例HER2低表达转移性乳腺癌患者接受[68Ga]Ga-ABY-025 PET/CT及配对肿瘤活检,未发生不良事件。
- 所有患者均见ABY-025摄取病灶,示踪剂摄取存在个体内和个体间异质性。
- 8例ABY-025摄取病灶经免疫组化或原位杂交确认HER2低表达,2例活检免疫组化评分为0。
核心结论
- [68Ga]Ga-ABY-025 PET/CT可视化HER2低表达转移性乳腺癌是可行且安全的。
- 示踪剂摄取区域显示不同程度的HER2表达。
- 观察到的个体内和个体间[68Ga]Ga-ABY-025摄取异质性提示HER2 PET可能用于无创评估疾病异质性,并有潜力识别可从HER2靶向药物临床获益的患者。
研究设计与样本
- 前瞻性先导研究,作为[68Ga]Ga-ABY-025在HER2表达实体瘤中的2期篮式显像研究的一部分。
- 纳入10例HER2低表达转移性乳腺癌患者(免疫组化评分1+或2+且无HER2基因扩增)。
- 患者在瑞典斯德哥尔摩卡罗林斯卡大学医院乳腺门诊招募。
- 注射200 MBq [68Ga]Ga-ABY-025后3小时行PET/CT,以SUVmax量化示踪剂摄取,超声引导肿瘤活检参考HER2 PET结果。
- 主要结局为HER2 PET在HER2低表达转移性乳腺癌患者中的安全性和可行性,测量可能的手术相关不良事件发生情况。
主要发现
- 10例HER2低表达转移性乳腺癌患者接受[68Ga]Ga-ABY-025 PET/CT及配对肿瘤活检,未发生不良事件。
- 所有患者均见[68Ga]Ga-ABY-025摄取病灶,示踪剂摄取存在显著个体内和个体间异质性。
- 10例中8例ABY-025摄取病灶经免疫组化或原位杂交确认HER2低表达。
- 2例肿瘤活检免疫组化评分为0:1例皮肤病灶SUVmax低,1例肝转移灶SUVmax高但核心“冷”。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with HER2-low metastatic breast cancer (mBC), defined as an immunohistochemistry (IHC) score of 1+ or 2+ without HER2 gene amplification, may benefit from HER2 antibody-drug conjugates. Identifying suitable candidates is a clinical challenge because of spatial and temporal heterogeneity in HER2 expression and discrepancies in pathologic reporting. We aimed to investigate the feasibility and safety of HER2-specific PET imaging with [68Ga]Ga-ABY-025 for visualization of HER2-low mBC. Methods: A prospective pilot study was done with 10 patients who had HER2-low mBC, as part of a phase 2 basket imaging study with [68Ga]Ga-ABY-025 in HER2-expressing solid tumors. Patients were recruited at the Breast Clinic at the Karolinska University Hospital, Stockholm, Sweden. PET/CT images were acquired 3 h after injection of 200 MBq of [68Ga]Ga-ABY-025. The SUVmax was used to quantify tracer uptake. Ultrasound-guided tumor biopsies were guided by results from the HER2 PET. The main outcome-the safety and feasibility of HER2 PET in patients with HER2-low mBC, measured the occurrence of possible procedure-related adverse events. Results: Ten patients with HER2-low mBC underwent [68Ga]Ga-ABY-025 PET/CT with paired tumor biopsies. No adverse events occurred. In all patients, [68Ga]Ga-ABY-025-avid lesions with substantial intra- and interindividual heterogeneity in tracer uptake were noted. In 8 of 10 patients with ABY-025-avid lesions, the HER2-low status of the corresponding lesions was confirmed by IHC or in situ hybridization. Two patients had an IHC score of 0 in the tumor biopsies:1 in a cutaneous lesion with a low SUVmax and 1 in a liver metastasis with a high SUVmax but a "cold" core. Conclusion: The visualization of HER2-low mBC with [68Ga]Ga-ABY-025 PET/CT was feasible and safe. Areas of tracer uptake showed varying levels of HER2 expression on IHC. The observed intra- and interindividual heterogeneity in [68Ga]Ga-ABY-025 uptake suggested that HER2 PET might be used as a tool for the noninvasive assessment of disease heterogeneity and has the potential to identify patients in whom HER2-targeted drugs can have a clinical benefit.
引用
- Altena R, Burén SA, Blomgren A, et al. Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [68Ga]Ga-ABY-025: Results from a Pilot Study. J Nucl Med. 2024. PMID: 38548353. doi:10.2967/jnumed.123.266847
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。